Aiming for label expansion, Merck touts new trial results for antibiotic Recarbrio

Merck
Merck's Recarbrio met primary and secondary endpoints in a phase 3 study in hospital-acquired and ventilator-associated bacterial pneumonia. (Merck)

You can't accuse Merck & Co. of giving up on antibiotics. This year, it's racked up a label expansion for Zerbaxa and a first-time approval for Recarbrio—and now it's touting new data that could win the newcomer an expansion.

Recarbrio, a combination of imipenem, cilastatin and relebactam, met its endpoints in a phase 3 test against hospital-acquired and ventilator-associated bacterial pneumonia in adult patients, Merck said Monday.  

That's the very label expansion Merck’s Zerbaxa won earlier this year, but more antibiotic options are sorely needed for patients with severe and sometimes fatal pneumonia, said Joan Butterton, Merck's associate vice president in infectious disease clinical research.

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

“When you have a patient with a bed infection, you sometimes know the infecting organism and you can test for resistance and you can see which antibiotic which will be able to fight that infection,” she said in an interview. “Many times, you need to make a decision prior to having culture and sensitivity."

RELATED: Merck's new combo med Recarbrio fights resistant bacteria. Can it tackle the sales challenge, too? 

The Restore-IMI 2 study tested Recarbrio against piperacillin/tazobactam and looked at day 28 all-cause mortality and clinical response as primary and secondary endpoints. Recarbrio hit both goals in the study, and Merck now plans to file the data with regulators for approval.

Recarbrio won its initial FDA nod in July to treat complicated urinary tract and abdominal infections when other treatments don't work. 

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.